. Guidelines recommend colonoscopy every 1 to 2 years. There is limited information about screening compliance in this high-risk group.
INTRODUCTION
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, is the most common inherited colorectal cancer (CRC) syndrome and accounts for 2 -5 % of cases of CRC ( 1 ) . LS is caused by germline mutations in mismatch repair (MMR) genes, and mutation carriers have increased risk for developing CRC, endometrial, ovarian, small intestinal, and urinary tract cancers ( 2 ) . Th e lifetime risk of CRC is 70 -80 % in the absence of colonoscopic screening, and many of these cancers develop in individuals before the age of 50 years. Most Lynch-associated CRCs show a phenotype of defective MMR gene function, which is associated with accelerated progression of colorectal adenomas to carcinomas. Clinical genetic testing for germline mutations in the MMR genes, hMLH1, hMSH2, and hMSH6 , and most recently in hPMS2 is available through commercial laboratories. Evaluating patients with CRC for a family history of cancer and evidence of defective mismatch repair in tumors (through tests for microsatellite instability and immunohistochemistry staining for MMR proteins) has been determined to be cost eff ective (3) , and published guidelines recommend genetic evaluation for individuals who meet Revised Bethesda guidelines ( 4 -6 ) .
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Colonoscopies provide an opportunity for early intervention in Lynch-associated colorectal neoplasia. In a Finnish cohort of individuals with LS who were off ered endoscopic surveillance, CRC-related mortality was reduced by > 60 % among those who underwent colonoscopies every 3 years ( 7 ). However, there are frequent reports of Lynch-associated CRCs arising within 3-year surveillance intervals (8, 9) , and guidelines for management of LS have recommended colonoscopy every 1 to 2 years, beginning at age 20 -25 years for those at risk ( 6, 10, 11 ) . Furthermore, because of the elevated risk of endometrial cancer, guidelines recommend that women undergo endometrial screening or prophylactic hysterectomy (6, 11) .
Small, single-institution studies have suggested that many individuals at risk for LS do not have CRC surveillance as frequently as guidelines specify ( 12 -16 ) . It is unclear whether inadequate CRC surveillance is the result of patient noncompliance or incorrect recommendations from physicians.
Th e objective of this multicenter study was to examine the prevalence of appropriate CRC surveillance among individuals at risk for LS and to identify clinical and demographic factors associated with appropriate CRC surveillance.
METHODS
We conducted a cross-sectional questionnaire study among individuals with a personal or family history of CRC who fulfi lled Bethesda guidelines for evaluation for LS ( 17 ) . Eligible individuals were identifi ed through one of four cancer genetics clinics (DanaFarber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; and University of California San Francisco, San Francisco, CA). Subjects had either visited one of these clinics themselves or were referred to the study by a family member who had been evaluated at one of these clinics. All participants were ≥ 18 years old and were able to read and write in English.
Potential subjects were invited to enroll in the study either at a clinical visit or by mail. Subjects who had visited a high-risk clinic and / or had undergone genetic testing were enrolled at least 3 months aft er the date of the clinic visit or disclosure of their genetic test result, whichever occurred later. Individuals approached by mail received an initial study packet with an introduction letter and questionnaire, as well as a decline to participate form. Th ose who did not return study materials aft er two follow-up telephone calls and two mailings were considered nonresponders. Questionnaire data were scanned and entered into a computerized database. Th e study was approved by the institutional review board of each participating study site.
Th e family history of cancer was obtained through a detailed family history questionnaire completed by subjects. In evaluating prevalence of appropriate CRC surveillance among individuals with LS, we limited the study population to include only those subjects who met strict clinical criteria for LS screening, defi ned as: (i) a family history that fulfi lled Amsterdam I or II criteria and / or (ii) the presence of a known pathogenic MMR gene mutation in the family. Subjects who had previously had genetic testing which revealed that they were not carriers of the family MMR mutation, and those who had molecular testing of their colorectal cancers which showed no evidence of defective mismatch repair (microsatellite stable and normal immunohistochemistry staining for MMR proteins), were not considered to be at risk for LS and therefore were excluded from this analysis.
Measures
Th e study questionnaires collected standard demographic information and data in the following domains.
Cancer risk perception . Perceived lifetime risk for developing various cancers (CRC, endometrial, breast, and prostate) was assessed using a 5-point Likert scale (very high, high, average, low, and very low) and a 0 -100 % likelihood scale.
Health and cancer surveillance . Personal history of cancer (type and age at diagnosis) and history of previous surgical resection(s) of the colon were elicited. Participants estimated how many doctor ' s visits they had in the previous 12 months and indicated the type of medical setting in which they received the majority of their cancer prevention care (private offi ce, health maintenance organization, community hospital, academic / teaching hospital, specialized cancer center, and other). Subjects were asked whether their physician had ever discussed their risk of developing cancer and whether he / she had recommended specifi c cancer screening tests. Subjects were asked how oft en they should undergo specifi c tests for cancer prevention. Frequency of tests, including colonoscopy, mammography, and digital rectal exam of the prostate, was elicited (choices included: more frequently than every year, every 1 year, every 2 years, every 3 years, every 4 -5 years, every 6 -10 years, less frequently than every 10 years, and other).
Screening compliance . Participants rated whether they had " all, " " some, " or " none " of the cancer screening tests recommended by their doctor and ranked the importance (on a 5-point Likert scale, 1 = not important to 5 = extremely important) of possible reasons why they did not have a specifi c cancer screening test (choices included: my doctor did not recommend it, I don ' t think I ' m at high risk, I think it will be uncomfortable, my insurance will not cover the cost, I fi nd the test embarrassing, if I had cancer I would rather not know, I have not had the time, and other) . Self-reported history of physician visits and age-appropriate health screenings were used to create a measure of compliance with standard preventive health maintenance. Subjects were classifi ed as being fully compliant with age-appropriate screening if they reported (i) visiting a health professional at least once in the previous 12 months and (ii) having yearly mammograms (women > 40 years only) or digital rectal exams of the prostate (men > 50 years only). Th ose who had not visited a physician in the past 12 months or who had not had age-appropriate breast or prostate screening were classifi ed as being partially compliant with their age-appropriate health maintenance.
Family history . Detailed family history was obtained, including diagnoses of various types of cancer among fi rst-, second-, and third-degree relatives.
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Insurance . Respondents were asked whether insurance issues had ever infl uenced the frequency of cancer screening tests, caused them to miss or delay cancer screening, or aff ected their decision to undergo genetic testing.
Our primary outcome measure of appropriate CRC surveillance for LS was defi ned as endoscopic examination of the colon at least every 2 years. Individuals > 25 years who did not report having a complete endoscopic exam of the colon at least every 2 years were classifi ed as having had inadequate CRC surveillance for LS. For those who had previously undergone an extensive colonic resection or subtotal colectomy, fl exible sigmoidoscopy every 2 years was considered appropriate.
Statistical analysis
Th e potential relationships between clinical and demographic factors and appropriate cancer surveillance were explored using univariate tests of association (Fisher ' s exact and t -tests). Age was examined as both a continuous and categorical variable ( < 40 years, 40 -49 years, and ≥ 50 years) using age thresholds based on published guidelines for CRC screening ( 18, 19 ) . Perceived risk of CRC was examined as continuous (0 -100 % ) and dichotomous ( higher-than-average risk vs. average / lower-than-average risk ) variables. Factors that were found to be statistically signifi cantly associated with appropriate cancer surveillance on univariate analysis or that were believed to have empiric clinical relevance were included in multivariable logistic regression models to identify those with a strong independent association with appropriate CRC surveillance. Generalized estimating equations were used to account for potential clustering of results among members of the same family. Analyses were performed using SAS Version 9.1 (Cary, NC) soft ware. All P values are two sided and a P value of < 0.05 was considered statistically signifi cant.
RESULTS
In all, 462 eligible individuals with a personal or family history of CRC who met Bethesda guidelines for LS were invited to participate in the study. Of these, 270 (58 % ) completed the study questionnaire, 34 (7 % ) declined to participate, and 158 (34 % ) were nonresponders. Women and college graduates were more likely to complete the study questionnaires. Th ere were no signifi cant diff erences in other demographic characteristics between study subjects and nonresponders.
Of these 270 individuals, 206 (76 % ) individuals who completed study questionnaires had a family history that either fulfi lled Amsterdam I or II Criteria for LS or included an identifi ed pathogenic MMR gene mutation in one or more relatives. Of these, 25 had undergone genetic testing, which confi rmed they were not carriers of a known family mutation (true-negative result), thereby leaving 181 individuals at a high risk for developing CRC associated with LS. Th e mean age of subjects was 46 years and 100 participants (55.3 % ) had a previous diagnosis of cancer. Only eight (4.4 % ) did not have health insurance. Of these 181 individuals, 136 (76 % ) had visited a high-risk clinic for genetic evaluation, 131(72.4 % ) had undergone genetic testing for LS, and 105 (58 % ) were known to be carriers of an identifi ed pathogenic mutation in a MMR gene. In addition, 35 (19 % ) of 181 subjects were enrolled in the study by mail, and of these subjects, 29 were referred to the study by family members. Th e additional participant characteristics are presented in Table 1 .
Out of 181 respondents, 170 (94 % ) reported they that had undergone a colonoscopy at least once. In addition, 130 (72 % ) had endoscopic screening of the colon every 2 years or more frequently and 2 individuals aged < 25 years had not yet undergone screening for CRC; thus, 132 (73 % ) out of 181 subjects were classifi ed as having appropriate CRC surveillance in accordance with LS guidelines. Th e univariate comparison of characteristics between those with appropriate vs. inadequate CRC surveillance is presented in Table 1 . Th ere were no signifi cant diff erences in age, gender, level of education, or previous history of colorectal adenomas between those who did and did not have appropriate CRC surveillance for LS.
Personal and family history of CRC
Prevalence of appropriate CRC surveillance was signifi cantly higher among individuals with a previous diagnosis of CRC, with 64 / 75 (85 % ) reporting colonoscopies at the appropriate 1-to 2-year interval, compared with only 68 / 106 (64 % ) of those without a CRC diagnosis ( P = 0.002). In examining family history of cancer, having greater numbers of relatives with CRC and / or a fi rst-degree relative with CRC diagnosed at age < 50 years were not signifi cantly associated with appropriate CRC surveillance on univariate analysis. However, subjects who reported having a family member with an identifi ed MMR gene mutation were significantly more likely to have appropriate CRC surveillance (85 / 103 (83 % ) vs. 47 / 78 (60 % ), P = 0.001).
Cancer risk perception and health practices
Overall, the perception of lifetime risk for developing CRC was very high and 81 % of subjects reported knowing they were at increased risk for CRC for 2 years or more. Mean cancer risk estimates did not diff er signifi cantly between those with appropriate vs. inadequate CRC surveillance (66.5 vs. 62.7 % lifetime risk for CRC, respectively). In all, 96 % of subjects reported making one or more visits to a doctor in the preceding 12 months and 85 % were fully compliant with age-appropriate breast or prostate cancer screening. Although having more doctor visits in the preceding 12 months was associated with appropriate CRC surveillance, there were no signifi cant diff erences in rates of age-appropriate breast and prostate cancer screening between those who had appropriate vs. inadequate CRC surveillance for LS ( P = 0.35).
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Risk assessment and genetic evaluation
A total of 144 (80 % ) respondents said their physician had discussed their cancer risk with them and 136 (76 % ) had been referred to a specialized " high risk " or genetics clinic for further evaluation. Of these 136 individuals referred for genetic evaluation, 109 (80 % ) reported having endoscopic screening of the colon at least every 2 years, compared with only 23 / 45 (51 % ) subjects who had not visited a specialty clinic or undergone genetic counseling ( P = 0.0004). In addition, 131 (72 % ) subjects had undergone genetic testing for MMR gene mutations associated with LS (13 subjects had genetic testing without visiting a specialized high-risk / genetics clinic). Th e prevalence of appropriate CRC surveillance among those who underwent genetic testing was high and did not diff er between subgroups whose DNA test results revealed a pathogenic MMR mutation compared with those with indeterminate / uninformative test results (89 / 105 (85 % ) vs. 21 / 26 (81 % ), P = 0.6). Th e history of a visit to a high-risk clinic for genetic counseling and personal history of genetic testing were each signifi cantly associated with appropriate CRC surveillance on univariate analysis ( P < 0.001). In all, 82 (63 % ) subjects who had been referred for genetic evaluation said they subsequently increased the frequency of their cancer screening. Prevalence of appropriate CRC surveillance was no diff erent between individuals who had their cancer prevention care at an academic medical center / cancer center vs. other health-care settings ( P = 0.5); however, those whose cancer prevention care was coordinated by a specialist (gastroenterologist, oncologist, and surgeon) were more likely to have endoscopic screening of the colon at appropriate intervals than those whose screening was coordinated by their primary care provider (24 / 24 (100 % ) vs. 100 / 145 (69 % ), respectively, P < 0.01).
Multivariable analysis
We used multivariable logistic regression to examine the relative eff ect of clinical and demographic factors on appropriate CRC surveillance. As there were only 49 participants who had inadequate CRC surveillance, the fi nal model was limited to fi ve variables to avoid overfi tting. Th e variable personal history of CRC (yes / no) was included based on the signifi cant association with appropriate CRC surveillance on univariate analysis. Th e variables, " fi rst-degree relative with CRC age < 50 " and subject age (in three categories: < 40, 40 -49, and ≥ 50 years), although not signifi cant on univariate analysis, were added because they are used for risk stratifi cation in published CRC screening algorithms ( 18, 19 ) . Th e variable " compliance with age-appropriate screening (full vs. partial) " was added to the model to control for potential associations between nonadherence with other cancer screening tests and CRC surveillance practices.
Th e variables, " genetic testing status " (odds ratio (OR) 6.84, 95 % confi dence interval (CI) 3.13 -14.12), " visit to a high-risk clinic " (OR 4.04, 95 % CI 1.95 -8.37), and " MMR mutation in the family " (OR 2.74, 95 % CI 1.41 -5.33), were each signifi cantly associated with appropriate CRC surveillance in univariate analysis. However, because these variables were clinically and statistically correlated with each other ( P < 0.0001), and the vast majority (90 % ) of individuals who underwent genetic testing for MMR gene mutations had also visited a high-risk clinic, includ- Fisher's exact test was used for categorical variables, and t -test was used for continuous variables.
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Inadequate CRC surveillance
Of the 49 respondents who had inadequate CRC surveillance, 26 (53 % ) reported undergoing endoscopic screening of the colon every 3 -5 years and 13 (27 % ) had endoscopic exams less frequently than every 5 years. Only 10 (20 % ) individuals had never had a colonoscopy. In addition, 27 (55 % ) subjects thought their own interval for colonoscopy screening should be " every 2 years or more frequently, " and 23 (47 % ) reported that they had been compliant with every test that their physician had recommended and had not missed any exams. Reasons rated as moderately or extremely important for missing endoscopy exams included: (i) worry that the test would be uncomfortable ( n = 10) and / or embarrassing ( n = 6), (ii) insurance would not cover the cost of colonoscopy ( n = 9), (iii) their doctor had not recommended the test ( n = 8), and (iv) they had not had time to schedule the test ( n = 7). Only 2 individuals said they had avoided the endoscopy exams because they would rather not know whether they had cancer. Surprisingly, only 12 / 49 (24 % ) of those with inadequate CRC surveillance reported that their physician had recommended an endoscopic screening interval of every 1 to 2 years.
DISCUSSION
As a potentially preventable cancer, CRC has been the target of recent public health campaigns and uptake of CRC screening tests is increasing. Individuals with a personal or family history of CRC or adenomatous polyps stand to benefi t most from screening, and current guidelines recommend diff erent tests and surveillance intervals based on whether an individual ' s cancer risk is estimated as average, moderately increased, or very high ( 18 ) . In a recent survey, 69 % of Maryland residents aged ≥ 50 years were " up to date " with CRC screening, and 59 % had undergone a colonoscopy in the past 10 years ( 20 ) . In our study, 73 % of individuals who met clinical criteria for LS had appropriate surveillance with colonoscopies every 1 to 2 years, which suggests there is room for improvement in cancer prevention among patients at the highest risk for CRC. Studies of CRC screening in US populations have identified various factors associated with test uptake, such as the level of education, income, having health insurance, participating in other cancer screening tests, and receiving a recommendation from their physician for CRC screening ( 21 ) . In this sense, the sociodemographic characteristics of the highly motivated subjects in our study cohort would predict that they would be ideal participants in CRC screening and, indeed, 94 % reported having had at least one colonoscopy. However, only 2 in 3 " cancer unaffected " individuals at highest risk for CRC had colonoscopies at intervals necessary to prevent Lynchassociated neoplasms.
Th ese fi ndings diff er dramatically from reports from Finland and the Netherlands, where centralized cancer registries coordinate genetic testing and cancer screening for individuals with hereditary cancer syndromes and compliance with CRC surveillance among individuals with LS approaches 98 % ( 22, 23 ) . In contrast, in the United States, the responsibility for identifying ing ≥ 2 of these in the same multivariable model resulted in model instability. Placing each of these variables in the model individually yielded comparable parameter estimates and we chose the variable " genetic testing status " as the surrogate for genetic evaluation for the fi nal multivariable model. Th e results of the multivariable model are presented in Table 2 . Genetic evaluation (OR 4.62, 95 % CI 1.66 -12.87), personal history of CRC (OR 2.81, 95 % CI 1.12 -7.04), and having a fi rst-degree relative with CRC at age < 50 years (OR 2.61, 95 % CI 1.23 -5.53) were each independent predictors of appropriate CRC surveillance for LS. We performed supplemental analyses to explore what component(s) of genetic evaluation were most important in infl uencing compliance with surveillance. Modifying the analysis to examine genetic evaluation in four categories ((i) high-risk clinic visit and DNA testing, (ii) high-risk clinic visit without DNA testing, (iii) DNA testing without a high-risk clinic visit, and (iv) neither high-risk clinic visit nor DNA testing) showed that genetic evaluation, which included both a visit to a high-risk clinic and DNA testing, remained the strongest predictor of appropriate CRC surveillance for LS (OR 6.16, 95 % CI 1.76 -21.55). In this expanded model, undergoing a genetic counseling visit without genetic testing or having genetic testing alone without counseling were not signifi cant predictors; however, the numbers of individuals in these categories were small and our power to evaluate these associations was limited. (12, 24) , and simply referring patients for CRC screening because of " family history " may not be sufficient to ensure appropriate care of individuals at risk for hereditary CRC syndromes. In our cohort, half of subjects who had inadequate cancer surveillance reported having colonoscopies every 3 -5 years, as recommended by their physicians. Although this interval would be appropriate for patients categorized as at " increased familial risk " in CRC screening guidelines ( 18 ), it is not frequent enough to prevent a signifi cant number of Lynchassociated CRCs ( 7, 8 ) .
Although it is not a surprise that individuals who had been diagnosed with CRC or who had a close relative with youngonset CRC were more likely to have appropriate surveillance, the fi nding that genetic evaluation is strongly associated with appropriate surveillance deserves attention. Current guidelines recommend genetic evaluation for individuals with personal or family histories who meet criteria for LS (10) , and cost-eff ectiveness analyses support microsatellite instability and immunohistochemistry testing of selected CRC tumors ( 3 ) on the assumption that identifying high-risk individuals will improve outcomes. To date, evidence that genetic evaluation for LS improves compliance with CRC surveillance has come from a few small studies: a Dutch study of 94 MMR gene mutation carriers found that the prevalence of colonoscopic screening increased from 31 % to 88 % aft er genetic testing ( 16 ) and two US studies of 22 and 32 MMR gene mutation carriers each found that subjects increased their uptake of colonoscopy aft er receiving a positive genetic test result ( 14, 15 ) . Our large multicenter study of 181 individuals at risk for LS (including 105 MMR gene mutation carriers) found a strong association between genetic evaluation and appropriate CRC surveillance. Of those who underwent genetic evaluation, 63 % reported that they subsequently increased cancer screening. CRC surveillance was appropriate in 80 % of subjects who had undergone genetic evaluation compared with 51 % in those who had not. Th e benefi t of genetic evaluation was the same, regardless of the outcome of the genetic test (prevalence of appropriate CRC surveillance was 84 % for subjects found to carry MMR gene mutations and 81 % for those with indeterminate genetic test results). Th is suggests that the process of genetic evaluation (which at our centers includes genetic counseling, DNA testing, and a clinical visit with physicians with expertise in managing hereditary CRC), rather than just the result of the DNA test, may be an important intervention in educating patients and physicians about the need for specialized CRC surveillance and screening for other extracolonic cancers.
How can we improve CRC surveillance among those at highest risk? Our fi ndings suggest that physician recommendations, rather than patient noncompliance, may be an important target for intervention. CRC screening should not be considered " one size fi ts all " ; discussions about CRC screening should include a detailed review of the patient ' s family history. Current CRC screening algorithms are stratifi ed by cancer risk and include specifi c recommendations for individuals at high risk for genetic syndromes ( 18 ) . Although clinical diagnostic criteria for LS remain complex, a number of web-based models allow clinicians to enter a patient ' s personal and family history and obtain a predicted probability that he / she carries an MMR gene mutation ( 25 -27 ) . When individuals are referred for genetic evaluation, it is crucial that results of testing and recommendations for cancer surveillance be discussed with patients and communicated back to the referring physicians to ensure successful follow-up.
We recognize that our study has certain limitations. Our study was conducted in a selected population of individuals who had direct or indirect contact with a cancer genetics clinic and who agreed to spend 30 min in completing a questionnaire. Consequently, these were highly motivated individuals who were aware of their family history of CRC. Th e primary outcome of appropriate cancer surveillance was assessed based on subjects ' self-reports of colonoscopy frequency and we were unable to obtain medical record confi rmation for many of these reports. However, previous investigations have validated the reliability of patient self-reports of endoscopic exams (28 -30) , and a number of studies, including the US National Health Interview Surveys (NHIS), collect information about CRC screening practices using subject interviews. In this cohort we expected that the frequency of colonoscopic exams was more likely to be overreported, rather than underreported. Consequently, we believe our fi nding that 73 % of individuals had colonoscopies every 1 to 2 years is probably an overestimation of the true prevalence of appropriate CRC surveillance among individuals at risk for LS. We acknowledge that our fi nding of a strong association between genetic evaluation and appropriate CRC surveillance does not permit us to diff erentiate whether the eff ect is attributable to the DNA test itself or to the clinical consultation with specialists in management of hereditary CRC. Th e clinical genetic evaluations performed at our centers included pre-and post-test genetic counseling, as is recommended by multiple organizations ( 5, 31, 32 ) . Because 90 % of subjects in this study who had DNA testing for MMR gene mutations had also had genetic counseling, we cannot determine whether genetic testing in the absence of specialist consultation and genetic counseling would aff ord the same benefi t.
Despite these limitations, our data from this large multicenter US study show that many patients at the highest risk for CRC are not screened at intervals necessary for cancer prevention. Among our highly motivated subjects, those who already had a CRC diagnosis, had a fi rst-degree relative with CRC diagnosed at age < 50 years, and / or had undergone genetic evaluation were signifi cantly more likely to have colonoscopies at intervals necessary to prevent Lynch-associated CRC. Physician recommendations for less frequent colonoscopies, rather than patient noncompliance, seemed to be an important reason why subjects had colonoscopies less frequently than every 1 to 2 years. With CRC screening strategies moving toward less-invasive testing at less frequent intervals, our fi ndings reinforce the need for physician -patient discussions about CRC risk that incorporate a detailed family history. As more patients at risk for LS are identifi ed through clinical and molecular
